MedTrace Logo

Pharmacokinetic Study of MIN-101 in Healthy Subjects

NCT02232529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-02-24

No results posted yet for this study

Summary

The aim of the study is to assess how MIN-101 is taken up by the body when given in different amounts and in different formulations. The drug will be given as a single dose in Part 1 of the study and during Part 2 of the study as multiple dose, once daily for 7 days. The ultimate aim is to find an optimal formulation which can be developed as a once daily dose for the treatment of schizophrenia.

Conditions

Interventions

DRUG

MIN-101

DRUG

Placebo

Sponsors & Collaborators

  • Minerva Neurosciences

    lead INDUSTRY

Principal Investigators

  • Pui Leung, M.D · Quotient Clinical

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United Kingdom

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232529 on ClinicalTrials.gov